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Although  described  for the ﬁrst  time  some  decades  ago,  the contribution  of the  immune
system  to the  establishment  of tumors  has  not  been  extensively  pursued  for  a long  time.
Over the last  decade,  however,  more  and  more  evidence  has  been  accumulating  concerning
the role the immune  system  plays  in tumor  development  and  progression  and  its possible
role in patient  prognosis.  In addition,  interest  is  growing  in  preclinical  and  clinical  research
concerning  the use  of  the immune  system  in the  treatment  of  cancer.  Immunotherapy  for
gynecological  cancers  in  general,  and  for endometrial  cancer  in  particular,  is still  in itsndometrial cancer
mmunotherapy infancy.  Only a small  number  of  studies,  with  varying  success  rates,  have  been  published.
Here,  we  provide  a concise  overview  of the  literature  available  on  the  role  of the  immune
system  in the  normal  endometrium  and  in  endometrial  cancer,  in addition  to the  possible
implications  for future  immunotherapeutic  studies.
©  2015  Elsevier  Ireland  Ltd.  All rights  reserved.. Introduction
Many risk factors involved in the etiology of endome-
rial cancer have been described. Obesity and physical
nactivity are two signiﬁcant risk factors for the devel-Please cite this article in press as: Vanderstraeten, A., et al., 
implications for endometrial cancer development. J. Reprod. Imm
pment of uterine tumors, along with elevated blood
ressure, high energy intake, high serum glucose lev-
ls and increased exposure to estrogens (Amant et al.,
Abbreviations: BMI, body mass index; COX-2, cyclo-oxygenase 2;
RP, C-reactive protein; CTL, cytotoxic T lymphocyte; DC, dendritic cells;
LA-G, human leukocyte antigen G; IDO, indoleamine 2,3-dioxygenase;
ALT, mucosa-associated lymphoid tissue; MDSC, myeloid-derived
uppressor cells; MHC, major histocompatibility complex; NF-B,
uclear factor kappa-light-chain-enhancer of activated B cells; PGE2,
rostaglandin E2; TDLN, tumor-draining lymph nodes; TAM, tumor-
ssociated macrophages; Treg, regulatory T cells.
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165-0378/© 2015 Elsevier Ireland Ltd. All rights reserved.2005). For some of these risk factors, the effects on
and interactions with the immune system have been
reported. Hormonal ﬂuctuations during the menstrual
cycle have been described to modulate immune functions,
as reviewed by Wira et al. (2010). Hormonal ﬂuctuations
and interactions with immune cells result in a protective
environment against invading pathogens, while creating
a favorable environment for embryonic implantation and
fetal development. Obesity, which is related to an increased
risk of developing endometrial cancer, is considered to be
a chronic inﬂammatory state, causing increased release of
pro-inﬂammatory cytokines such as IL-6 and CRP (Visser
et al., 1999).
In addition to the effect of the risk factors described on
the immune system, the vast majority of endometrial can-
cer cases are diagnosed in post-menopausal women andThe immune system in the normal endometrium and
unol. (2015), http://dx.doi.org/10.1016/j.jri.2014.12.006
often in elderly patients. Age has an important inﬂuence
on the immune system, the so-called immunosenescence,
which parallels hormonal changes that occur with increas-
ing age (Pﬁster and Savino, 2008). Aging causes an overall
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decrease in immune-related functions and results in a
latent pro-inﬂammatory state.
Taken together, these data indicate that risk factors
associated with the occurrence of endometrial cancer have
an important inﬂuence on the immune system. In the
current review, we provide an overview of the role the
immune system plays in the normal non-pregnant uterus
and how changes in the immune system may  play a role in
the development of uterine tumors and the possible clin-
ical outcome. This knowledge is important for successful
further development of immunotherapeutic strategies for
uterine cancer.
2. The uterine immune system under physiological
conditions and in cancer
The immune system in the normal uterus serves a dual
purpose. On the one hand, it plays a role in protection
against pathogens, while on the other hand, it has the abil-
ity to adapt to an immunosuppressive state in order to
create feto-maternal tolerance toward a semi-allogeneic
fetus. These separate functions involve the complex inter-
play of the hormonal ﬂuctuations of the menstrual cycle
and the immune system. Normal endometrium is naturally
under strict hormonal control. It is under constant control
of the variations in estradiol and progesterone during the
menstrual cycle. Both the innate and adaptive arms of the
immune system are inﬂuenced by these hormonal changes.
Several risk factors have been described for endometrial
cancer, which may  be linked to increased inﬂammation
of the endometrial tissue, as reviewed by Modugno et al.
(2005). Increased exposure to estrogens has been shown
to be associated with endometrial cancer development,
owing to the mitogenic effect of estrogens (Austin et al.,
1991; Potischman et al., 1996; Zeleniuch-Jacquotte et al.,
2001). Consequently, estrogen-related carcinogenesis may
be related to inﬂammatory events. Chronic inﬂamma-
tion has been linked to cancer development (Hanahan
and Weinberg, 2011). Several inﬂammation pathways are
involved in carcinogenesis. Many of these pathways are
initialized by, among others, activation of STAT 3 or NF-
B (Elinav et al., 2013). The detailed role these pathways
and their downstream mediators play in carcinogenesis is
beyond the scope of this review and is brieﬂy summarized
in Fig. 1. This interplay is discussed and further elaborated
on by Elinav et al. (2013).
2.1. Immune functions of normal and malignant
endometrial cells
The endometrial epithelium serves as the primary line
of defense against viruses and other pathogens entering
the uterus. The epithelial cells form an integral part of the
mucosal immune system. Next to forming a physical bar-
rier, the epithelial cells have several direct immune-related
functions, one of which is the secretion of defensins (Wira
et al., 2005b). Defensins form a part of the innate immunePlease cite this article in press as: Vanderstraeten, A., et al.,
implications for endometrial cancer development. J. Reprod. Imm
system, considering their immediate antimicrobial func-
tion and their ability to activate the adaptive immune
system. For example, defensins have been shown to attract
T cells and immature dendritic cells (DC) in response to PRESS
ive Immunology xxx (2015) xxx–xxx
binding to the C-C chemokine receptor type 6 (CCR6) (Yang
et al., 1999). Other secreted molecules include macrophage
inﬂammatory protein (MIP)3,  also a ligand for CCR6, and
secretory leukocyte protease inhibitor (SLPI) (Fahey and
Wira, 2002; Fahey et al., 2006a). In contrast, uterine epithe-
lial cells secrete unidentiﬁed, soluble immune mediators
that confer a tolerogenic phenotype to DC (Ochiel et al.,
2010).
Obesity and diabetes have also been shown to be
associated with increased release of pro-inﬂammatory
molecules, such as IL-6, TNF-, CRP, leptin, and
macrophage migration inhibitory factor (Dandona et al.,
2004; Visser et al., 1999). Two studies evaluating the
serum levels of IL-6, TNF-, and CRP, and the risk of
developing endometrial cancer, have shown that elevated
levels of CRP are associated with endometrial cancer risk
(Friedenreich et al., 2013; Wang et al., 2011). Wang et al.
(2011) found this correlation after correcting for BMI  and
age. Friedenreich et al. (2013), in addition, found that CRP
and endometrial cancer risk were associated with high
BMI, and that serum IL-6 and endometrial cancer risk were
associated with low BMI.
Indoleamine 2,3-dioxygenase (IDO), which is responsi-
ble for T cell suppression through the deprivation of the
crucial metabolite tryptophan, is up-regulated in secre-
tory versus proliferative endometrium. The presence of the
enzyme may  play a dual protective role: it functions as an
anti-bacterial agent and induces suppression of T cells. The
latter creates an immunosuppressive state to allow embry-
onic implantation (Lobo et al., 2004). IDO is also expressed
by endometrial carcinoma cells (de Jong et al., 2012; Ino
et al., 2008; Vanderstraeten et al., 2014), and was proven
to be associated with myometrial invasion, lymph node
metastases and lymphovascular space involvement (Ino
et al., 2008). In addition, high IDO expression correlated
with decreased CD8+ TIL and NK cell involvement and was
associated with poor survival (de Jong et al., 2012). Thus,
in both normal and malignant endometrium, the primary
function of IDO seems to be the induction of immuno-
suppression in order to allow embryonic implantation or
tumor growth.
Endometrial epithelial cells are also potent antigen-
presenting cells. Ferguson et al. found expression of major
histocompatibility complex (MHC) class I in endometrial
glands and in stromal cells and endothelial cells. MHC
class II, on the contrary, was found to be expressed in
the endometrial glands in approximately 50% of normal
endometrium samples (Ferguson et al., 1985). Fahey et al.
have shown that cultured epithelial cells express CD40
and CD1d and that epithelial cells in addition to stromal
endometrial cells can elicit tetanus toxoid-speciﬁc T cell
responses (Fahey et al., 2006b; Wallace et al., 2001). In
endometrial tumors, classical MHC  class I was  down-
regulated in 48.5% of 520 tumors, which is associated
with worse disease prognosis (Bijen et al., 2010). In
addition, the non-classical MHC  class I molecule, human
leukocyte antigen G (HLA-G) was up-regulated in 39.8% The immune system in the normal endometrium and
unol. (2015), http://dx.doi.org/10.1016/j.jri.2014.12.006
of samples, corroborating the results of Barrier et al., who
found expression of HLA-G in 55% of samples (Barrier
et al., 2006). Although requiring further investigation, the
up-regulation of HLA-G molecules in endometrial tumors
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Fig. 1. Inﬂammatory signaling and carcinogenesis. Pro-inﬂammatory cytokines induce signal transducer and activator of transcription 3 (STAT3) and
nuclear  factor-B (NF-B) signaling in cancer cells, which leads to the suppression of apoptosis and the promotion of cell cycle progression. Inﬂammasome-
dependent interleukin-22 binding protein (IL-22BP) secretion inhibits IL-22-driven STAT3 induction. Genomic destabilization can be promoted by cytokine-
mediated ectopic expression of activation-induced cytidine deaminase (AID) and by hypoxia-dependent suppression of DNA repair mechanisms. In addition,
STAT3  and NF-B signaling also induces epithelial–mesenchymal transition (EMT) by down-regulating the expression of epithelial differentiation markers.
ASC,  apoptosis-associated speck-like protein containing a CARD; HIF1, hypoxia-inducible factor 1; IL-1R, IL-1 receptor; MYD88, myeloid differentiation
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eproduced with permission from Elinav et al. (2013).
ay  be a protective mechanism to avoid NK cell lysis in
he case of the down-regulation of MHC  class I molecules,
s shown in other tumors (Ibrahim et al., 2001; Paul et al.,
998). MHC  class II was found to be present in only a small
ortion of malignant endometrial cells. The scant presence
f both the classical MHC  I and II molecules in addition to
he up-regulation of the non-classical HLA-G indicate the
oor antigen-presenting capacity of endometrial tumor
ells (Lazaris et al., 2004; Tamiolakis et al., 2005). Cells in
he underlying stroma, however, do show MHC  II positivity
Lazaris et al., 2004). Taken together, normal endometrial
ells can present antigens in the context of MHC  molecules,
robably as a defense mechanism to pathogens. Endome-
rial tumor cells, however, down-regulate the expressionPlease cite this article in press as: Vanderstraeten, A., et al., 
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f MHC  molecules to mediate immune escape.
Last, several members of the B7-H family have been
escribed. We  recently described the presence of these
olecules in both normal endometrium and uterine, transforming growth factor-; TNF, tumor necrosis factor; TNFR, TNF
tumors (Vanderstraeten et al., 2014). We  found expres-
sion of PD-L1 (B7-H1), and B7-H4 in the vast majority of
normal endometria, while PD-L2 (B7-DC) was present in
approximately half of normal endometria, albeit at low
levels. All of these molecules were also present in endome-
trial cancer (Vanderstraeten et al., 2014). When comparing
the expression levels of all molecules, we  did not ﬁnd up-
regulation in endometrial tumors. Although the population
investigated was  fairly small for a sound analysis, a trend
toward decreased survival was found in PD-L1+ tumors
(Vanderstraeten et al., 2014). Our results on B7-H4 are
contradictory to those of a previously published study, in
which B7-H4 was reported to be signiﬁcantly up-regulated
in endometrial tumors (Miyatake et al., 2007; Qian et al.,The immune system in the normal endometrium and
unol. (2015), http://dx.doi.org/10.1016/j.jri.2014.12.006
2011). The expression pattern of this molecule was  mainly
cytoplasmic in conjunction with strong circumferential
staining and has been shown to negatively correlate with
the number of TIL, both the T cell population as a whole
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(CD3+) and the separate CTL population (CD8+) (Miyatake
et al., 2007). For the latter, this correlation was also found
for B7-H3 (Brunner et al., 2012). These data indicate that,
since for most of these mediators no up-regulation was
found in endometrial tumors, these molecules may  also
exert their immunosuppressive functions in both the nor-
mal  and the cancerous situation, as described above for IDO.
2.2. Inﬁltration by immune cells
Apart from the mediators just discussed, which can
attract immune cells, immune cells themselves are present
as part of endometrial tissue. The exact nature of the
immune cells present in endometrial tissue/tumors and
their function will be elaborated on below. A schematic
representation of the presence of immune cells in normal
endometrium is given in Fig. 2A and the main players in the
tumor microenvironment are depicted in Fig. 2B. Table 1
gives a concise overview of the immunological players in
endometrium and endometrial tumors and their implica-
tions for tumor biology.
2.2.1. Innate immune cells
Macrophages represent approximately 10% of the total
cellular population of the endometrium. They are mostly
present in the endometrial stroma and myometrial connec-
tive tissue (Wira et al., 2005a). Their frequency is highest
before menstruation, as is the frequency of neutrophils.
The latter plays a role in the breakdown of the endome-
trial tissue at menstruation and in the elevation of immune
protection during the disruption of the protective bar-
rier of the endometrial epithelium (Hickey et al., 2011).
Macrophages play a paradoxical role in cancer, in a sense
that they can have both a pro- and anti-tumorigenic func-
tion (Ohno et al., 2004). Tumor-associated macrophages
(TAM) located in the focal necrotic center of the tumor
and TAM at the tumor margin correlated with disease
progression and with clinicopathological features of the
tumor (Ohno et al., 2004; Soeda et al., 2008). TAM at the
tumor margin were associated with the formation of lymph
node metastases, indicating tumor progression, whereas
macrophages in the tumor nest, the bulky area of the tumor
surrounding the tumor center, were associated with bet-
ter, relapse-free survival. This may  be explained by local
factors within the tumor, exerting different functions on
macrophages. The tumor center, for example, is known
to be hypoxic. This is suggested to trigger the angiogenic
capacities of macrophages, leading to renewed oxygen sup-
ply and tumor progression (Ohno et al., 2004). Another
cell type, such as macrophages derived from the myeloid
lineage, are myeloid-derived suppressor cells (MDSC). To
date, to our knowledge, MDSC have only been described
in endometrial cancer by our own group (Vanderstraeten
et al., 2014). MDSC analysis was subdivided into the pres-
ence of monocytic MDSC (lin−HLA-DR−/loCD11b+CD14+)
and granulocytic MDSC (lin−HLA-DR−/loCD11b+CD14−).Please cite this article in press as: Vanderstraeten, A., et al.,
implications for endometrial cancer development. J. Reprod. Imm
MDSC of both the monocytic and granulocytic types were
found, although most of the population identiﬁed were of
the granulocytic type. This subtype has been described to
have the strongest suppressive capacity compared to the PRESS
ive Immunology xxx (2015) xxx–xxx
monocytic subtype (Raber et al., 2014), providing evidence
of increased immunosuppression in endometrial tumors.
The largest representative of the innate immune
system, however, is natural killer cells (NK cells). As
for the cells described above, their numbers in normal
endometrium vary depending on the phase in the cycle.
The highest number of NK cells is found in the secretory
phase of the cycle. At this point NK cells represent about
70% of the total leukocyte population (Wira et al., 2005a).
This is likely the result of both increased IL-15 levels in the
endometrium in the secretory phase and of an increased
NK cell inﬂux from peripheral blood (Lobo et al., 2004).
However, research by Manaster et al. showed that the
percentage of NK cells remains relatively constant at
approximately 30% of the total lymphocyte population
(Manaster et al., 2008). Male et al. found precursor NK cells,
so-called stage 3 NK cells in uterine mucosa, in addition to
mature, stage 4, NK cells (Male et al., 2010). The authors
postulate that stage 3 NK cells (CD34−CD117+CD94+)
migrate into the uterus where they mature to obtain
their distinct phenotype (CD34−CD117−/+CD94+) (Male
et al., 2010). Uterine NK cells are different from their
counterparts in blood (Yang et al., 2011). Like NK cells
in blood, they express CD94, CD56, and CD9, but do not
express CD16, CD8 or CD57. In addition, CD56 is expressed
at about ten-fold higher levels in uterine NK cells than in
blood NK cells (Yang et al., 2011). Little has been described
concerning the functional differences of peripheral blood
NK cells and uterine NK cells. NK cells in both proliferative
and secretory phase endometrium have been shown to be
inert cells that lack both their cytotoxic capacity and their
ability to secrete cytokines. However, this can be reverted
when the cells are cultured in the presence of IL-15
(Manaster et al., 2008). Stimulation with IL-15 resulted
in the up-regulation of the activating NK cell receptors,
NKp30 and NKp44, but no difference in the expression of
NKp46 and NKG2D was found. In addition, IL-15 activated
endometrial NK cells showed increased in vitro cyto-
toxic capability and secreted IP-10 (CXCL-10) and IFN-
(Manaster et al., 2008). Uterine NK cells are thus suggested
to be inert lymphocytes without the cytotoxic capabilities
of peripheral NK cells. These NK cells are inactive during
the normal menstrual cycle and are suggested to mature
to fully functional NK cells during pregnancy (Manaster
et al., 2008). There are only a few studies focusing on NK
cells in endometrial carcinoma patients. NK cell activity in
peripheral blood against K562 cells was found to decrease
with an increase in histological differentiation grade and
myometrial invasion in early stage (stage I) endometrial
carcinoma (Garzetti et al., 1994). A study already published
in 1987 by Timonen et al. in eight endometrial cancer
patients and one endometrial stromal sarcoma patient
showed that unstimulated peripheral blood lymphocytes
show cytotoxic responses against autologous tumor and
against HeLa cells in seven out of nine patients (Timonen
et al., 1987). This activity was  increased upon the addition
of recombinant IL-2. The IL-2-activated lytic precursor The immune system in the normal endometrium and
unol. (2015), http://dx.doi.org/10.1016/j.jri.2014.12.006
cells belong to the subpopulation of lymphocytes that
includes NK cells (Timonen et al., 1987). Ferguson et al.
found that NK cells were virtually absent in endometrial
tumors (Ferguson et al., 1985). Intratumoral NK cells were
Please cite this article in press as: Vanderstraeten, A., et al., The immune system in the normal endometrium and
implications for endometrial cancer development. J. Reprod. Immunol. (2015), http://dx.doi.org/10.1016/j.jri.2014.12.006
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Fig. 2. The immune system in the normal uterus and in uterine cancer. (A) Fluctuations in the immune system in the normal menstrual cycle. During
the  proliferative phase up until the secretory phase, NK cells and macrophages proliferate and the lymphoid aggregates increase in size. The increased
frequencies corroborate their function in the breakdown of the endometrium. CD1d+ dendritic cells (DC) increase in frequency, while CD83+ DC remains
constant, possibly indicating DC migration. During the secretory phase, both indoleamine 2,3-dioxygenase (IDO) and the frequency of Treg are increased to
create  an immunosuppressive environment for possible embryonal implantation. Dashed rectangles indicate the location of the endometrium in which the
cells  reside. (B) The immune system in endometrial cancer. In contrast to the situation in normal endometrium, major histocompatibility complex (MHC)
class  I/II molecules are down-regulated, facilitating immune escape, while human leukocyte antigen G (HLA-G) is up-regulated. In addition, myeloid-
derived suppressor cell (MDSC) inﬁltrates are described in uterine tumors and DC have been shown to down-regulate costimulatory molecules. For T cells
(including Treg) and macrophages, their exact function and the resulting effect on outcome are dependent on the location within the tumor/at the tumor
margin.
ARTICLE IN PRESSG ModelJRI-2291; No. of Pages 10
6 A. Vanderstraeten et al. / Journal of Reproductive Immunology xxx (2015) xxx–xxx
Table 1
Overview of immunological mediators in uterine tumors.
Molecule/cell type Normal endometrium Uterine tumors
Available data Correlation with
clinicopathology
Relation to prognosis
MHC class I Expressed Down-regulated Down-regulated in
advanced and
undifferentiated
tumors
Worse prognosis
MHC class II Expressed in ∼50% of cases Present in minority of
tumor cells
HLA-G Conﬂicting data Up-regulated
IDO Up-regulated in secretory phase Up-regulated Associated with
myometrial invasion,
lymph node metastases
and lymphovascular
space involvement
Associated with poor survival
NK  cells Increase during menstrual cycle Low levels, increased
upon progestin
treatment
Activity decreased in
advanced disease
Macrophages Increase during menstrual cycle Location-dependent
pro- or anti-tumor
effects
Location-dependent Location-dependent
Neutrophils Increase during menstrual cycle Increased Increased NLR
associated with lymph
node metastasis
DC  Low levels Increased Negatively correlated
with the clinical stage
and lymph node
metastasis
B  cells Present in aggregates
T cells Present in aggregates Conﬂicting data Dependent on location and phenotype
Treg  Increase during menstrual cycle Increased compared
with blood
Increased in advanced
disease
Worse prognosis
MDSC Unknown Present with higher
frequency of
granulocytic subtype
Unknown
en G, ID
utrophiMHC: major histocompatibility complex, HLA-G: human leukocyte antig
Treg: regulatory T cells, MDSC: myeloid-derived suppressor cells, NLR: ne
analyzed immunohistochemically in endometrial carci-
noma patients following progestin treatment (Witkiewicz
et al., 2010). After treatment with progestin, the total
cytotoxic (granzyme B+) lymphocyte population in the
tumors increased 6.5-fold. While CD56+ NK cells were
present in low numbers or absent pre-treatment, the NK
cell frequency rose to 76% of the total cytotoxic (granzyme
B+) cell population in endometrial lesions, which showed
signs of regression. On the contrary, in lesions of a stable or
progressive nature, no increase in NK cells was noted. CD8+
CTL showed a mild increase in regressing lesions, while
they remained approximately constant in stable or pro-
gressive lesions. Thus, progestin treatment can attract NK
cells into uterine tumors, which is associated with disease
improvement. In addition, these ﬁndings can explain the
increased level of NK cells in the secretory phase of normal
endometrium, when progesterone levels are highest.
Dendritic cells (DC) were also described in the human
endometrium, at relatively low levels compared with other
immune cells (Schulke et al., 2008). Throughout the cycle,
these cells reside both in the functional and the basalPlease cite this article in press as: Vanderstraeten, A., et al.,
implications for endometrial cancer development. J. Reprod. Imm
layers. The frequency of immature CD1a+ DC increases
during the cycle, while the mature CD83+ DC population
remains relatively constant. This indicates that, in accor-
dance with their natural function, mature dendritic cellsO: indoleamine 2,3-dioxygenase, NK: natural killer, DC: dendritic cells,
l to lymphocyte ratio.
migrate from their resident tissue. In uterine tumors, HLA-
DR+ DC have been shown to be present in both the glandular
cells and the interstitial tissue (Lijun et al., 2012). The func-
tional capacity of tumor-inﬁltrating DC, however, has been
shown to be compromised in uterine tumors, owing to
the signiﬁcantly reduced expression of the costimulatory
molecules CD86, CD80, and CD40 compared with DC in
normal endometrium (Jia et al., 2012).
2.2.2. Adaptive immune cells
T and B cells, both members of the adaptive immune
system, can also be found in the normal endometrium.
They are present in uterine mucosa as unique aggregates
consisting of a B cell core surrounded by T cells. Addi-
tionally, these structures are surrounded by a capsule of
macrophages and monocytes (Yeaman et al., 1997). These
structures have been suggested to be similar to the mucosa-
associated lymphoid tissue (MALT), which can be found in
the gastrointestinal system (Marshall and Jones, 1988). The
T cells present in these aggregates are almost exclusively
CD8+ CD45RO+, indicating that they are memory type effec- The immune system in the normal endometrium and
unol. (2015), http://dx.doi.org/10.1016/j.jri.2014.12.006
tor cells (Yeaman et al., 2001). These aggregates have been
shown to increase in size from the proliferative phase, at
this point without the B cell core, until the secretory phase
of the menstrual cycle. In addition, they are absent in the
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enopause, indicating that their expansion is hormone-
riven (Yeaman et al., 1997). This is further exempliﬁed by
he observation that T cells within the aggregate express
strogen receptors (Tabibzadeh and Satyaswaroop, 1989).
dditionally, Yeaman et al. have shown that the accumu-
ation of T cells is the result of T cell migration toward the
ndometrium, rather than a proliferation of single resident
 cell clones (Yeaman et al., 2001).
The function of these aggregates is largely unknown.
owever, they may  serve a purpose in both the creation
f an immunosuppressive environment to allow feto-
aternal tolerance on the one hand and on the other hand
o create an environment that protects against pathogens
uring menstruation, when the epithelial barrier is dis-
upted. The former is exempliﬁed by the observation that
he cytotoxic T lymphocytes in the proliferative phase of
he cycle have cytotoxic capacity, while this function is
everely dampened in the secretory phase, during which
onception can occur (White et al., 1997). In addition, CD8+
 cells are still capable of exerting their full cytotoxic func-
ion, further indicating that during the secretory phase of
he menstrual cycle, a temporary state of immunosuppres-
ion occurs to allow possible embryonic implantation. The
ifference in the cytotoxic capacity of T cells during the
ifferent phases of the menstrual cycle is subject to hor-
onal control to maintain the balance between immune
rotection and tolerance (White et al., 1997). The latter
unction of the lymphoid aggregates is supported by the
ocation from which they originate. During the prolifera-
ive phase, the aggregates expand from within the basalis
troma, the inner third of the endometrium that is not shed
uring menstruation. Consequently, the lymphoid aggre-
ates may  provide immune protection against pathogens
uring menstruation. Alternatively, the presence of these
ggregates in the basalis stroma may  be a means of preven-
ing the loss of T and B cells during menstruation (Yeaman
t al., 1997). This type of lymphoid structures, recently
ermed tertiary lymphoid structures, resemble the MALT
ound in the gastrointestinal system, as mentioned above.
hese structures have been described in several tumor
ypes, such as colorectal cancer, lung cancer, melanoma,
varian cancer, renal cell cancer, and breast cancer (Goc
t al., 2013). The co-localization of both T and B lym-
hocytes in these aggregates has been shown to correlate
ith improved patient survival (Nielsen and Nelson, 2012).
n uterine tumors, MALT-like structures have not been
escribed to date, but tumor-inﬁltrating lymphocytes (TIL)
ave been shown in different studies. Chang et al. found
hat CD8+ TIL showed less expression of granzyme B and
erforin than their blood counterparts, indicating possible
unctional defects or tumor-induced suppression (Chang
t al., 2010). However, in vitro activation of TIL resulted
n adequate activation of TIL and induction to the same
olarization proﬁle as found in peripheral blood (i.e., main
olarization to Th1-type cells). TIL have been associated
ith prognosis in endometrial cancer, with contradictory
eports. The prognostic value of this inﬁltrate depends onPlease cite this article in press as: Vanderstraeten, A., et al., 
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he location within the tumor. Increased numbers of TIL,
f unspeciﬁed composition, at the invasive margin of the
umor (i.e., the tumor–myometrial junction) did not have
 beneﬁcial effect on patient survival according to a study PRESS
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by Silverberg et al. (1982). These results were contradicted
by Kondratiev et al., who  found that, although conﬁrming
the presence of CD8+ TIL at the tumor-invasive margin,
the presence of these TIL was  associated with improved
prognosis (Kondratiev et al., 2004). However, the latter
study only considered CD8+ TIL at the invasive border,
while Silverberg et al. considered the total lymphocyte
population, which may  explain these different ﬁndings.
Two additional studies investigated the total lymphocyte
population at the invasive margin (Ambros and Kurman,
1992; Deligdisch, 1982). Deligdisch observed that the pres-
ence of an inﬁltrate consisting of lymphocytes and plasma
cells, potentially indicating the described tertiary lymphoid
structures, appeared to be related to low-grade endome-
trial tumors, and suggested that TIL might be associated
with a favorable prognosis (Deligdisch, 1982). A later study
by Ambros and Kurman refuted this suggested associa-
tion (Ambros and Kurman, 1992). Intratumoral CD8+ TIL
have been associated with improved disease-free survival
in both type I and type II endometrial cancer (de Jong et al.,
2009). These intratumoral TIL were found more frequently
in low-grade tumors than in high-grade tumors. The pres-
ence of CD45RO+ T cells, indicating memory T cells, was  also
shown. Moreover, the presence of memory T cells was  asso-
ciated with increased overall survival and with reduced
events of recurrence (de Jong et al., 2009). Chang et al.
described the majority of tumor-inﬁltrating CD8+ T cells
as being CD28−CD45RA−CD45RO+, deﬁning terminally dif-
ferentiated T cells. In addition, the T cells appeared to be in
an activated state, exempliﬁed by the expression of CD69,
CD103, and CD152 (Chang et al., 2010). In the proximal
tumor-draining lymph nodes (TDLN), the CD4/CD8 ratio is
increased (Fattorossi et al., 2004). In addition, Yamamoto
et al. found that clonally expanded T cells are absent from
TDLN in patients with local endometrial tumors, while
clonally expanded T cells could be retrieved from TDLN
and peripheral blood in patients suffering from metastatic
cancer, supporting the role of immune responses to solid
tumors (Yamamoto et al., 1995). This speciﬁc appearance
of T cell clones in the TDLN of metastatic tumors may be
a consequence of direct T cell priming by (metastasized)
tumor cells present in the TDLN in metastatic tumors. This
results in the expansion of T cell clones in the affected
lymph nodes. This direct priming does not occur in unaf-
fected lymph nodes, as is the case in early-stage disease
(Contassot et al., 2009). The results of Yamamoto et al.
expand the earlier ﬁndings of Garzetti et al. (1995), who did
not ﬁnd any clinical signiﬁcance in the lymphocyte distri-
bution in lymph nodes in patients with early-stage disease.
In addition, Garzetti et al. showed that myometrial invasion
with or without lymphovascular space involvement was
associated with increased CD16+ and CD56+ cells, deﬁning
NK cells, in pelvic nodes (Garzetti et al., 1995).
Regulatory T cells (Treg) have a natural function to sup-
press ongoing immune responses when they are no longer
necessary. However, this may  also cause suppression of
an antitumor immune response. Treg have been shown toThe immune system in the normal endometrium and
unol. (2015), http://dx.doi.org/10.1016/j.jri.2014.12.006
be increased in the peripheral blood of normal controls in
the late follicular phase (Arruvito et al., 2007). Analysis of
the Treg frequency in the endometrium showed that Treg
are only infrequently present in the endometrium and that
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their frequency is higher in the proliferative phase than
in the secretory phase (El-Hamarneh et al., 2013). Collec-
tively, these data indicate that the frequency of Treg cells
appears to increase during the proliferative phase and is
reduced after ovulation.
Several studies have reported the presence of Treg in
endometrial carcinoma. Intratumoral Treg are increased
compared with peripheral blood (Chang et al., 2010). In this
particular study it was also shown that, like CTL, intratu-
moral Treg also express granzyme B, indicating the capacity
to lyse effector cells. However, Treg in stromal tissue were
found to be signiﬁcantly lower in tumor than in nor-
mal  endometrium (Giatromanolaki et al., 2008). Although
lower, high tumoral Treg counts were shown to correlate
with increased vascularity (Giatromanolaki et al., 2008),
tumor grade, stage, the extent of lymph node metastases
and myometrial invasion (Chang et al., 2010) in addition
to worse disease-free survival (Yamagami et al., 2011). The
latter has also been shown to result from the presence of
high Treg/CD8 and Treg/CD4 ratios (Yamagami et al., 2011).
In distal TDLN, the proportion of functional regulatory T
cells is increased (Fattorossi et al., 2004).
Taken together, the ﬂuctuations of the different
immunological cell types during the normal menstrual
cycle are a further indication of the dual role the immune
system plays in the uterus, as described earlier. The
immunosuppressive capacity that certain cell types, such
as Treg, have within the framework of feto-maternal toler-
ance also contributes to immune escape by tumors. Some
cell types, such as macrophages and T cells, appear to have
a different effect on the outcome of a tumor, depending
on the location in which they reside. This likely indi-
cates that at different sites within the tumor or the tumor
microenvironment the immune system may  be differen-
tially inﬂuenced in such a way that the functional capacities
of the immune cells are inﬂuenced toward either an anti-
tumor or a pro-tumor proﬁle.
3. Clinical implications
The currently reviewed data provide an insight into sev-
eral immune mechanisms in uterine tumors and indicate
possible options for therapeutic modalities. The compo-
sition of the intratumoral immune inﬁltrate may  have
an important inﬂuence on treatment outcome. This phe-
nomenon has recently been described in ovarian cancer
(Zhang et al., 2003). It was shown that the ﬁve-year survival
rate of ovarian cancer patients who underwent debulking
surgery and received adjuvant chemotherapy was  at least
six times higher in patients with an intratumoral T cell inﬁl-
trate in the tumor islet, compared with patients without
a T cell inﬁltrate (Zhang et al., 2003). Therefore, strate-
gies could be developed to skew the unfavorable immune
inﬁltrate in certain patients into a more immunogenic
microenvironment to enhance the efﬁcacy of conventional
treatment in these patients. Several negative immune reg-
ulators are present and possibly active in endometrialPlease cite this article in press as: Vanderstraeten, A., et al.,
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cancer. Of the currently reviewed regulators, several could
present as valuable targets for therapeutic intervention.
First, IDO and PD-L2 are useful targets, although only
in a limited percentage of tumors (Vanderstraeten et al., PRESS
ive Immunology xxx (2015) xxx–xxx
2014). Several trials are currently ongoing to evaluate the
use of IDO inhibitor 1-methyltryptophan (registered at
www.clinicaltrials.gov). No studies were listed to evalu-
ate the use of an IDO inhibitor in endometrial cancer.
Several trials are currently ongoing to evaluate its use,
either in combination with other treatments for ovarian
cancer and peritoneal tumors or alone. Both PD-L1 and
B7-H4 could represent targets in EMCAR, because of their
high expression levels. Antibodies directed against PD-L1,
or the receptor PD-1, are being used in trials for several
solid tumors. Anti PD-L1 treatment resulted in objective
response rates ranging from 6% to 17% in patients with
solid tumors, including melanoma, renal cell carcinoma,
and non-small cell lung cancer, while anti-PD-1 led to
objective response rates of up to 27% (Brahmer et al., 2012;
Topalian et al., 2012). MDSC also represent a valuable tar-
get in endometrial cancer. Preliminary data of a clinical
trial evaluating MDSC targeting with the use of all trans-
retinoic acid (ATRA) showed promising results. In small cell
lung cancer patients, co-treatment with a DC vaccine and
ATRA resulted in a substantial increase in immune response
after vaccination, as exempliﬁed by an increase in IFN--
secreting antigen-speciﬁc T cells (Iclozan et al., 2013).
Last, the presence of NK cells in uterine tumors cor-
relates with a beneﬁcial treatment outcome in uterine
tumors. This provides motivation for the use of adoptive
NK cell therapy in uterine tumors, which remains to be
explored.
4. Conclusion
The data outlined here clearly show that the immune
system is present and active in both normal endometrium
and endometrial tumors. In the normal endometrium, the
immune system plays a central role in protection against
pathogens and in safeguarding feto-maternal tolerance.
Like this dual role in a healthy situation, it also has both
a pro- and anti-tumorigenic function. In our opinion, the
interplay between positive and negative players and mech-
anisms in tumor development and progression provides
possible intervention options in the treatment of endome-
trial cancer, which deserves further attention in future
research.
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